Zelong Liu

Beijing Technology and Business University

Also affiliated with Zhengzhou University of Light Industry, Hunan Agricultural University

ChemistryAgricultural and Biological SciencesEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy”.

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.26.525680

N/A

0.165DataRank · unranked

2 citations

Zohreh Amoozgar, Xin Liu, Shuichi Aoki, Zelong Liu, Sarah M. Shin +17 more

Inflammasome targeting with an NLRP3 agonist therapy is feasible but ineffective in murine hepatocellular carcinoma models with liver damage

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.06.23.497362

N/A

0DataRank · unranked

0 citations

Zelong Liu, Chen Jiang, Koetsu Inoue, Zhiping Ruan, Lingling Zhu +5 more

IFNA pathway drives the more aggressive phenotype of KRAS G12D -mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.06.29.497540

N/A

0DataRank · unranked

0 citations

Daniel H. Schanne, Aya Matsui, Pin‐Ji Lei, Sebastian Klein, Shuichi Aoki +20 more

Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma

Nature Communications(2025)10.1038/s41467-025-66581-3

N/A

0DataRank · unranked

2 citations

Zelong Liu, Chengzhan Zhu, Tatsuya Kobayashi, Pin‐Ji Lei, Yue Shi +14 more